The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Nils Wierup

Nils Wierup

Research team manager

Nils Wierup

Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion.


  • Valeriya Lyssenko
  • Cecilia Nagorny
  • Michael R Erdos
  • Nils Wierup
  • Anna Jonsson
  • Peter Spégel
  • Marco Bugliani
  • Richa Saxena
  • Malin Fex
  • Nicolo Pulizzi
  • Bo Isomaa
  • Tiinamaija Tuomi
  • Peter Nilsson
  • Johanna Kuusisto
  • Jaakko Tuomilehto
  • Michael Boehnke
  • David Altshuler
  • Frank Sundler
  • Johan G Eriksson
  • Anne U Jackson
  • Markku Laakso
  • Piero Marchetti
  • Richard M Watanabe
  • Hindrik Mulder
  • Leif Groop

Summary, in English

Genome-wide association studies have shown that variation in MTNR1B (melatonin receptor 1B) is associated with insulin and glucose concentrations. Here we show that the risk genotype of this SNP predicts future type 2 diabetes (T2D) in two large prospective studies. Specifically, the risk genotype was associated with impairment of early insulin response to both oral and intravenous glucose and with faster deterioration of insulin secretion over time. We also show that the MTNR1B mRNA is expressed in human islets, and immunocytochemistry confirms that it is primarily localized in beta cells in islets. Nondiabetic individuals carrying the risk allele and individuals with T2D showed increased expression of the receptor in islets. Insulin release from clonal beta cells in response to glucose was inhibited in the presence of melatonin. These data suggest that the circulating hormone melatonin, which is predominantly released from the pineal gland in the brain, is involved in the pathogenesis of T2D. Given the increased expression of MTNR1B in individuals at risk of T2D, the pathogenic effects are likely exerted via a direct inhibitory effect on beta cells. In view of these results, blocking the melatonin ligand-receptor system could be a therapeutic avenue in T2D.


  • Department of Experimental Medical Science
  • Genomics, Diabetes and Endocrinology
  • Celiac Disease and Diabetes Unit
  • Internal Medicine - Epidemiology

Publishing year







Nature Genetics





Document type

Journal article


Nature Publishing Group


  • Endocrinology and Diabetes



Research group

  • Genomics, Diabetes and Endocrinology
  • Celiac Disease and Diabetes Unit
  • Internal Medicine - Epidemiology


  • ISSN: 1546-1718